Renalytix Plc (NASDAQ:RNLX) Short Interest Down 15.3% in April

Renalytix Plc (NASDAQ:RNLX) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 673,700 shares, a drop of 15.3% from the March 31st total of 795,200 shares. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Renalytix

Institutional investors have recently added to or reduced their stakes in the business. Pinnacle Associates Ltd. raised its stake in shares of Renalytix by 7.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 846,534 shares of the company’s stock valued at $330,000 after acquiring an additional 60,572 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Renalytix in the third quarter valued at $547,000. Finally, Pentwater Capital Management LP increased its holdings in Renalytix by 5.9% in the third quarter. Pentwater Capital Management LP now owns 598,440 shares of the company’s stock valued at $958,000 after purchasing an additional 33,440 shares during the period. 9.92% of the stock is owned by institutional investors.

Renalytix Stock Performance

RNLX opened at $0.63 on Monday. The company’s 50 day moving average is $0.88 and its 200-day moving average is $0.71. Renalytix has a 1-year low of $0.24 and a 1-year high of $4.04.

Renalytix (NASDAQ:RNLX) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Renalytix had a negative net margin of 1,736.47% and a negative return on equity of 1,008.88%. The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.70 million.

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.